Investors
Mauna Kea Technologies
Stock Information
Mauna Kea Technologies
Stock Information
Stay up to date on all our investor news
0,1762€
Last updated
23/05/2026 - 10:00
-2,54%
€7.6m
Total sales in 2024
+40
Commercial opportunities following CellTolerance launch
+48%
PPU growth in 2024 vs.
2022
excluding exchange rates
Events and Presentations
Financial Results
Governance
AGM 2026 – Resolutions
No results found.
AGM 2026 – Candidate Profiles
No results found.
AGM 2026 – Notice of Meeting for Registered Shareholders
No results found.
AGM 2026 – Board’s Report on Resolutions
No results found.
2025 Annual Financial Report (free translation)
No results found.
News
Mauna Kea Technologies Expands Presence in the Middle East with UAE and Turkey Regulatory Approvals and First CellTolerance® Commercial Installation
Mauna Kea Technologies Announces Nomination of 3 New Directors
Publication of the 2025 Annual Financial Report
No results found.
Shareholding Structure
A long term vision shared by major strategic shareholders: Johnson & Johnson (NYSE: JNJ) and Telix Pharmaceuticals (ASX : TLX)
Stock Information
STOCK MARKET DATA
Listed on Euronext Growth Paris
Initial listing : July 6, 2011
The number of outstanding shares is : 79,439,997
Industry : healthcare (4000)
Sector : Medical equipment and healthcare services (4530)
IDENTIFICATION CODES
ISIN : FR0010609263
Ticker : ALMKT
ANALYST COVERAGE
ALLINVEST SECURITIES
Thibaut Voglimacci – Stephanopoli
EUROLAND CORPORATE
EUROLAND CORPORATE
Raphaël Génin
STATUTORY AUDITORS
• EY and Others, represented by Mr Franck SEBAG, 1-2 place des Saisons, 92400 Courbevoie- Paris La Défense, France